Cargando…

Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey

BACKGROUND: The Philadelphia chromosome−negative myeloproliferative neoplasms (MPN) myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) negatively affect patient quality of life (QoL) and are associated with increased risk of mortality. METHODS: The MPN Landmark survey was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mesa, Ruben, Miller, Carole B., Thyne, Maureen, Mangan, James, Goldberger, Sara, Fazal, Salman, Ma, Xiaomei, Wilson, Wendy, Paranagama, Dilan C., Dubinski, David G., Boyle, John, Mascarenhas, John O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769833/ https://www.ncbi.nlm.nih.gov/pubmed/26922064 http://dx.doi.org/10.1186/s12885-016-2208-2

Ejemplares similares

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey
por: Mesa, Ruben A., et al.
Publicado: (2016)

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey
por: Yu, Jingbo, et al.
Publicado: (2019)

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
por: Harrison, Claire N., et al.
Publicado: (2017)

Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey
por: Yu, Jingbo, et al.
Publicado: (2018)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey
por: Byun, Ja Min, et al.
Publicado: (2022)

Renal biopsy cases in myeloproliferative neoplasms (MPN)
por: Fujita, Kumi, et al.
Publicado: (2013)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Thromboinflammation in Myeloproliferative Neoplasms (MPN)—A Puzzle Still to Be Solved
por: Bhuria, Vikas, et al.
Publicado: (2022)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Casetti, I. C., et al.
Publicado: (2022)

Recruitment strategies and geographic representativeness for patient survey studies in rare diseases: Experience from the living with myeloproliferative neoplasms patient survey
por: Yu, Jingbo, et al.
Publicado: (2020)

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021)

Oxygen-18 Kinetic Isotope Effects of Nonheme Iron Enzymes HEPD and MPnS Support Iron(III) Superoxide as the Hydrogen Abstraction Species
por: Zhu, Hui, et al.
Publicado: (2015)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
por: Barbui, Tiziano, et al.
Publicado: (2022)

Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN)
por: Price, Gregory L., et al.
Publicado: (2014)

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report
por: Hoshino, Yoshitomo, et al.
Publicado: (2023)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Wille, Kai, et al.
Publicado: (2023)

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis
por: Aoyama, Yumi, et al.
Publicado: (2019)

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry
por: Gecht, Judith, et al.
Publicado: (2021)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL
por: Wang, Xiaoli, et al.
Publicado: (2023)

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2020)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature
por: Yadav, Ruchi, et al.
Publicado: (2023)

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
por: Hasselbalch, Hans Carl, et al.
Publicado: (2015)

Biology and therapeutic targeting of molecular mechanisms in MPNs
por: How, Joan, et al.
Publicado: (2023)

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients
por: Palmer, Jeanne M., et al.
Publicado: (2020)

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)
por: Zulkeflee, Razan Hayati, et al.
Publicado: (2021)

The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis
por: Chia, Yuh Cai, et al.
Publicado: (2021)

Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2021)

Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN
por: Benlabiod, Camélia, et al.
Publicado: (2020)

PB2058: IMPACT OF COMORBIDITIES AND RESPONSE TO TREATMENT ON THE MPN SAF ASSESSMENT OF PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE SYNDROMES.
por: Mohamed, B., et al.
Publicado: (2022)

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey
por: Palandri, Francesca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ckp1rk5slu3i9mkbknrelive72